Independent review not only defuses the content of short arguments, it also is important so that the FDA can make good decisions regarding which designations will be assigned to expedite the upcoming phase II trials. I disagree that we do not have competent people to handle the shorts. Other companies have not faired as well with a short/af onslaught. Our company picked up Woodford during that time.
News 
Market Data 
Discover 
